Skip to content

Because every patient has the right
to expect treatment

  • English
Menu
  • English
  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
Menu
  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
  • News
  • Contact
Menu
  • News
  • Contact
  • English
Menu
  • English
  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
  • News
  • Contact
Menu
  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
  • News
  • Contact

News

  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
  • News
  • Contact
Menu
  • About CTRS
    • Our company
    • The president’s words
    • Our team
  • Your health
    • Multiple myeloma
    • Primary bile acid synthesis disorders
  • Our products
  • Our R&D
  • News
  • Contact

Launch of Exploring (rare) cholestasis

  • March 17, 2021
Read more

Passing of Christian Cailliot, Director of R&D

  • March 8, 2021
Read more

Rare disease day at CTRS

  • February 28, 2021
Read more

CTRS is part Growth Champions 2021!

  • February 5, 2021
Read more

Partnership between CTRS and Unicancer

  • December 17, 2020
Read more

Repositioning drugs: a real opportunity for rare diseases?

  • December 15, 2020
Read more
« previous Page1 Page2 Page3 Next »
  • Terms of use
  • Site map
  • Cookies policy
Menu
  • Terms of use
  • Site map
  • Cookies policy

Follow us